Advancing research on regulatory autoantibodies targeting GPCRs: Insights from the 5th international symposium

Otavio Cabral-Marques; Lena F. Schimke; Guido Moll; Igor Salerno Filgueiras; Adriel Leal Nóbile; Anny Silva Adri; Fernando Yuri Nery do Vale; Júlia Nakanishi Usuda; Yohan Lucas Gonçalves Corrêa; Débora Albuquerque; Roseane Galdioli Nava; Ronaldy Santana Santos; Haroldo Dutra Dias; Hélio Fernandes Silva; Pedro Batista Marconi; Rusan Catar; Michael Adu-Gyamfi; Pinchao Wang; Taj Ali Khan; Alexander M. Hackel; Anja Leheis; Anja Stähle; Antje Müller; Carolin Schmidt; Chiara Radunovic; El Baraa Adjailia; Hanna Grasshoff; Jens Y. Humrich; Jonas Menz; Konstantinos Fourlakis; Maike Winziers; Maj Jäpel; Manuel Vincent Wegner; Peter Lamprecht; Relana Nieberding; Reza Akbarzadeh; Sabrina Arnold; Sebastian Jendrek; Sebastian Klapa; Solveig Augustin; Sophie Biedermann; Susanne Schinke; Patrick Scheerer; Matthias Endres; Kai Schulze-Forster; Friedemann Paul; Xinhua Yu; Franziska Sotzny; Thomas P. Sakmar; Miroslaw Banasik; Aiden Haghikia; Markus H. Hoffmann; Dmitry Veprintsev; Torsten Witte; Rodrigo J.S. Dalmolin; Hans D. Ochs; Harald Heidecke; Carmen Scheibenbogen; Yehuda Shoenfeld; Gabriela Riemekasten

doi:10.1016/j.autrev.2025.103855

Advancing research on regulatory autoantibodies targeting GPCRs: Insights from the 5th international symposium

Otavio Cabral-Marques^*, Lena F. Schimke, Guido Moll, Igor Salerno Filgueiras, Adriel Leal Nóbile, Anny Silva Adri, Fernando Yuri Nery do Vale, Júlia Nakanishi Usuda, Yohan Lucas Gonçalves Corrêa, Débora Albuquerque, Roseane Galdioli Nava, Ronaldy Santana Santos, Haroldo Dutra Dias, Hélio Fernandes Silva, Pedro Batista Marconi, Rusan Catar, Michael Adu-Gyamfi, Pinchao Wang, Taj Ali Khan, Alexander M. HackelAnja Leheis, Anja Stähle, Antje Müller, Carolin Schmidt, Chiara Radunovic, El Baraa Adjailia, Hanna Grasshoff, Jens Y. Humrich, Jonas Menz, Konstantinos Fourlakis, Maike Winziers, Maj Jäpel, Manuel Vincent Wegner, Peter Lamprecht, Relana Nieberding, Reza Akbarzadeh, Sabrina Arnold, Sebastian Jendrek, Sebastian Klapa, Solveig Augustin, Sophie Biedermann, Susanne Schinke, Patrick Scheerer, Matthias Endres, Kai Schulze-Forster, Friedemann Paul, Xinhua Yu, Franziska Sotzny, Thomas P. Sakmar, Miroslaw Banasik, Aiden Haghikia, Markus H. Hoffmann, Dmitry Veprintsev, Torsten Witte, Rodrigo J.S. Dalmolin, Hans D. Ochs, Harald Heidecke, Carmen Scheibenbogen, Yehuda Shoenfeld, Gabriela Riemekasten^*

^*Corresponding author for this work

3 Citations (Scopus)

Abstract

The 5th International Symposium on Regulatory Autoantibodies Targeting GPCR (RAB-GPCRs) advanced the understanding of the significant role played by autoantibodies targeting G-protein-coupled receptors (GPCRs) in various human diseases. Once considered passive markers, RAB-GPCRs are now recognized as active modulators of cellular signaling, immune regulation, and inflammation. The symposium highlighted their involvement in multiple prominent pathologies, including autoimmune diseases, cardio- and cerebrovascular diseases, and neuroimmunologic disorders such as myalgic encephalomyelitis/chronic fatigue syndrome and post-COVID-19 syndrome (ME/CFS/PCS), as well as solid organ and hematopoietic stem cell transplantation (SOT/HSCT). Experts from rheumatology, immunology, and neurology presented interdisciplinary discussions on the potential of RAB-GPCRs as biomarkers and therapeutic targets. Advances in screening methods, biomarker identification, and therapeutic strategies were shared, emphasizing their diagnostic potential and application in novel therapeutic interventions. This report summarizes key insights from the symposium, particularly focusing on the modulatory properties of RAB-GPCRs and their relevance in both immune-mediated diseases and other pathologies (e.g., vascular, degenerative) that are traditionally not considered primarily immune-mediated. Ongoing research is expected to further establish these autoantibodies as crucial components in disease modulation and systems biology contexts, offering new opportunities for precision medicine and improved clinical outcomes in immune-related disorders.

Original language	English
Article number	103855
Journal	Autoimmunity Reviews
Volume	24
Issue number	9
ISSN	1568-9972
DOIs	https://doi.org/10.1016/j.autrev.2025.103855
Publication status	Published - 29.08.2025

Funding

Funders	Funder number
Bundesministerium für Bildung und Forschung
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Berlin-Brandenburger Centrum für Regenerative Therapien
Berlin-Brandenburg School for Regenerative Therapies	GSC203
Horizon 2020 Framework Programme	754995, 101095635, 733006, 779293
PROEX	88887.699840/2022-00, 130027/2023-5
Deutsche Forschungsgemeinschaft	394046635, #CA2816/1-1, 01EJ2204A
Fundação de Amparo à Pesquisa do Estado de São Paulo	2018/18886-9, 2023/12268-0, 40013/2025-3, 2024/08016-8, 2020/16246-2, 2023/14417-2, 2023/07806-2
Conselho Nacional de Desenvolvimento Científico e Tecnológico	309482/2022-4

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

DFG Research Classification Scheme

2.21-05 Immunology
2.22-18 Rheumatology

Access to Document

10.1016/j.autrev.2025.103855

Cite this

Cabral-Marques, O., Schimke, L. F., Moll, G., Filgueiras, I. S., Nóbile, A. L., Adri, A. S., do Vale, F. Y. N., Usuda, J. N., Corrêa, Y. L. G., Albuquerque, D., Nava, R. G., Santos, R. S., Dias, H. D., Silva, H. F., Marconi, P. B., Catar, R., Adu-Gyamfi, M., Wang, P., Khan, T. A., ... Riemekasten, G. (2025). Advancing research on regulatory autoantibodies targeting GPCRs: Insights from the 5th international symposium. Autoimmunity Reviews, 24(9), Article 103855. https://doi.org/10.1016/j.autrev.2025.103855

@article{09a062b4d2cd4e46aebf2a2a2253f2e7,

title = "Advancing research on regulatory autoantibodies targeting GPCRs: Insights from the 5th international symposium",

abstract = "The 5th International Symposium on Regulatory Autoantibodies Targeting GPCR (RAB-GPCRs) advanced the understanding of the significant role played by autoantibodies targeting G-protein-coupled receptors (GPCRs) in various human diseases. Once considered passive markers, RAB-GPCRs are now recognized as active modulators of cellular signaling, immune regulation, and inflammation. The symposium highlighted their involvement in multiple prominent pathologies, including autoimmune diseases, cardio- and cerebrovascular diseases, and neuroimmunologic disorders such as myalgic encephalomyelitis/chronic fatigue syndrome and post-COVID-19 syndrome (ME/CFS/PCS), as well as solid organ and hematopoietic stem cell transplantation (SOT/HSCT). Experts from rheumatology, immunology, and neurology presented interdisciplinary discussions on the potential of RAB-GPCRs as biomarkers and therapeutic targets. Advances in screening methods, biomarker identification, and therapeutic strategies were shared, emphasizing their diagnostic potential and application in novel therapeutic interventions. This report summarizes key insights from the symposium, particularly focusing on the modulatory properties of RAB-GPCRs and their relevance in both immune-mediated diseases and other pathologies (e.g., vascular, degenerative) that are traditionally not considered primarily immune-mediated. Ongoing research is expected to further establish these autoantibodies as crucial components in disease modulation and systems biology contexts, offering new opportunities for precision medicine and improved clinical outcomes in immune-related disorders.",

author = "Otavio Cabral-Marques and Schimke, \{Lena F.\} and Guido Moll and Filgueiras, \{Igor Salerno\} and N{\'o}bile, \{Adriel Leal\} and Adri, \{Anny Silva\} and \{do Vale\}, \{Fernando Yuri Nery\} and Usuda, \{J{\'u}lia Nakanishi\} and Corr{\^e}a, \{Yohan Lucas Gon{\c c}alves\} and D{\'e}bora Albuquerque and Nava, \{Roseane Galdioli\} and Santos, \{Ronaldy Santana\} and Dias, \{Haroldo Dutra\} and Silva, \{H{\'e}lio Fernandes\} and Marconi, \{Pedro Batista\} and Rusan Catar and Michael Adu-Gyamfi and Pinchao Wang and Khan, \{Taj Ali\} and Hackel, \{Alexander M.\} and Anja Leheis and Anja St{\"a}hle and Antje M{\"u}ller and Carolin Schmidt and Chiara Radunovic and Adjailia, \{El Baraa\} and Hanna Grasshoff and Humrich, \{Jens Y.\} and Jonas Menz and Konstantinos Fourlakis and Maike Winziers and Maj J{\"a}pel and Wegner, \{Manuel Vincent\} and Peter Lamprecht and Relana Nieberding and Reza Akbarzadeh and Sabrina Arnold and Sebastian Jendrek and Sebastian Klapa and Solveig Augustin and Sophie Biedermann and Susanne Schinke and Patrick Scheerer and Matthias Endres and Kai Schulze-Forster and Friedemann Paul and Xinhua Yu and Franziska Sotzny and Sakmar, \{Thomas P.\} and Miroslaw Banasik and Aiden Haghikia and Hoffmann, \{Markus H.\} and Dmitry Veprintsev and Torsten Witte and Dalmolin, \{Rodrigo J.S.\} and Ochs, \{Hans D.\} and Harald Heidecke and Carmen Scheibenbogen and Yehuda Shoenfeld and Gabriela Riemekasten",

note = "Publisher Copyright: {\textcopyright} 2025 The Authors",

year = "2025",

month = aug,

day = "29",

doi = "10.1016/j.autrev.2025.103855",

language = "English",

volume = "24",

journal = "Autoimmunity Reviews",

issn = "1568-9972",

publisher = "Elsevier B.V.",

number = "9",

}

Cabral-Marques, O, Schimke, LF, Moll, G, Filgueiras, IS, Nóbile, AL, Adri, AS, do Vale, FYN, Usuda, JN, Corrêa, YLG, Albuquerque, D, Nava, RG, Santos, RS, Dias, HD, Silva, HF, Marconi, PB, Catar, R, Adu-Gyamfi, M, Wang, P, Khan, TA, Hackel, AM, Leheis, A, Stähle, A , Müller, A, Schmidt, C, Radunovic, C, Adjailia, EB , Grasshoff, H , Humrich, JY, Menz, J, Fourlakis, K, Winziers, M, Jäpel, M, Wegner, MV , Lamprecht, P, Nieberding, R, Akbarzadeh, R , Arnold, S , Jendrek, S, Klapa, S, Augustin, S , Biedermann, S , Schinke, S, Scheerer, P, Endres, M, Schulze-Forster, K, Paul, F, Yu, X, Sotzny, F, Sakmar, TP, Banasik, M, Haghikia, A, Hoffmann, MH, Veprintsev, D, Witte, T, Dalmolin, RJS, Ochs, HD, Heidecke, H, Scheibenbogen, C, Shoenfeld, Y & Riemekasten, G 2025, 'Advancing research on regulatory autoantibodies targeting GPCRs: Insights from the 5th international symposium', Autoimmunity Reviews, vol. 24, no. 9, 103855. https://doi.org/10.1016/j.autrev.2025.103855

TY - JOUR

T1 - Advancing research on regulatory autoantibodies targeting GPCRs

T2 - Insights from the 5th international symposium

AU - Cabral-Marques, Otavio

AU - Schimke, Lena F.

AU - Moll, Guido

AU - Filgueiras, Igor Salerno

AU - Nóbile, Adriel Leal

AU - Adri, Anny Silva

AU - do Vale, Fernando Yuri Nery

AU - Usuda, Júlia Nakanishi

AU - Corrêa, Yohan Lucas Gonçalves

AU - Albuquerque, Débora

AU - Nava, Roseane Galdioli

AU - Santos, Ronaldy Santana

AU - Dias, Haroldo Dutra

AU - Silva, Hélio Fernandes

AU - Marconi, Pedro Batista

AU - Catar, Rusan

AU - Adu-Gyamfi, Michael

AU - Wang, Pinchao

AU - Khan, Taj Ali

AU - Hackel, Alexander M.

AU - Leheis, Anja

AU - Stähle, Anja

AU - Müller, Antje

AU - Schmidt, Carolin

AU - Radunovic, Chiara

AU - Adjailia, El Baraa

AU - Grasshoff, Hanna

AU - Humrich, Jens Y.

AU - Menz, Jonas

AU - Fourlakis, Konstantinos

AU - Winziers, Maike

AU - Jäpel, Maj

AU - Wegner, Manuel Vincent

AU - Lamprecht, Peter

AU - Nieberding, Relana

AU - Akbarzadeh, Reza

AU - Arnold, Sabrina

AU - Jendrek, Sebastian

AU - Klapa, Sebastian

AU - Augustin, Solveig

AU - Biedermann, Sophie

AU - Schinke, Susanne

AU - Scheerer, Patrick

AU - Endres, Matthias

AU - Schulze-Forster, Kai

AU - Paul, Friedemann

AU - Yu, Xinhua

AU - Sotzny, Franziska

AU - Sakmar, Thomas P.

AU - Banasik, Miroslaw

AU - Haghikia, Aiden

AU - Hoffmann, Markus H.

AU - Veprintsev, Dmitry

AU - Witte, Torsten

AU - Dalmolin, Rodrigo J.S.

AU - Ochs, Hans D.

AU - Heidecke, Harald

AU - Scheibenbogen, Carmen

AU - Shoenfeld, Yehuda

AU - Riemekasten, Gabriela

PY - 2025/8/29

Y1 - 2025/8/29

N2 - The 5th International Symposium on Regulatory Autoantibodies Targeting GPCR (RAB-GPCRs) advanced the understanding of the significant role played by autoantibodies targeting G-protein-coupled receptors (GPCRs) in various human diseases. Once considered passive markers, RAB-GPCRs are now recognized as active modulators of cellular signaling, immune regulation, and inflammation. The symposium highlighted their involvement in multiple prominent pathologies, including autoimmune diseases, cardio- and cerebrovascular diseases, and neuroimmunologic disorders such as myalgic encephalomyelitis/chronic fatigue syndrome and post-COVID-19 syndrome (ME/CFS/PCS), as well as solid organ and hematopoietic stem cell transplantation (SOT/HSCT). Experts from rheumatology, immunology, and neurology presented interdisciplinary discussions on the potential of RAB-GPCRs as biomarkers and therapeutic targets. Advances in screening methods, biomarker identification, and therapeutic strategies were shared, emphasizing their diagnostic potential and application in novel therapeutic interventions. This report summarizes key insights from the symposium, particularly focusing on the modulatory properties of RAB-GPCRs and their relevance in both immune-mediated diseases and other pathologies (e.g., vascular, degenerative) that are traditionally not considered primarily immune-mediated. Ongoing research is expected to further establish these autoantibodies as crucial components in disease modulation and systems biology contexts, offering new opportunities for precision medicine and improved clinical outcomes in immune-related disorders.

AB - The 5th International Symposium on Regulatory Autoantibodies Targeting GPCR (RAB-GPCRs) advanced the understanding of the significant role played by autoantibodies targeting G-protein-coupled receptors (GPCRs) in various human diseases. Once considered passive markers, RAB-GPCRs are now recognized as active modulators of cellular signaling, immune regulation, and inflammation. The symposium highlighted their involvement in multiple prominent pathologies, including autoimmune diseases, cardio- and cerebrovascular diseases, and neuroimmunologic disorders such as myalgic encephalomyelitis/chronic fatigue syndrome and post-COVID-19 syndrome (ME/CFS/PCS), as well as solid organ and hematopoietic stem cell transplantation (SOT/HSCT). Experts from rheumatology, immunology, and neurology presented interdisciplinary discussions on the potential of RAB-GPCRs as biomarkers and therapeutic targets. Advances in screening methods, biomarker identification, and therapeutic strategies were shared, emphasizing their diagnostic potential and application in novel therapeutic interventions. This report summarizes key insights from the symposium, particularly focusing on the modulatory properties of RAB-GPCRs and their relevance in both immune-mediated diseases and other pathologies (e.g., vascular, degenerative) that are traditionally not considered primarily immune-mediated. Ongoing research is expected to further establish these autoantibodies as crucial components in disease modulation and systems biology contexts, offering new opportunities for precision medicine and improved clinical outcomes in immune-related disorders.

UR - https://www.scopus.com/pages/publications/105008694966

U2 - 10.1016/j.autrev.2025.103855

DO - 10.1016/j.autrev.2025.103855

M3 - Scientific review articles

C2 - 40543860

AN - SCOPUS:105008694966

SN - 1568-9972

VL - 24

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

IS - 9

M1 - 103855

ER -

Advancing research on regulatory autoantibodies targeting GPCRs: Insights from the 5th international symposium

Abstract

Funding

UN SDGs

Research Areas and Centers

DFG Research Classification Scheme

Access to Document

Other files and links

Fingerprint

Cite this